Proteoglycans and Collagen in Connective Tissue

Collagen and proteoglycans are the major components of the extracellular matrix in connective tissues, including bone, cartilage, tendon, ligament and skin. Collagen is the most abundant protein in mammals, 25-35% of total body protein, and provides the structural framework and tensile strength of those tissues. Proteoglycans are core proteins carrying negatively charged glycosaminoglycan (GAG) side chains that attract water, and aggrecan is the major proteoglycan of cartilage.

View larger

Why the chemistry matters. Mutations in the collagen genes cause heritable disease, and collagen structure explains the mechanism; the disorders are set against each collagen type below. Osteoarthritis involves proteoglycan loss and disruption of the collagen network, and intervertebral disc degeneration involves aggrecan degradation, so the pathology can only be understood against the normal structure.

Healing. Collagen synthesis is essential for fracture healing, tendon repair and wound closure. Type III collagen appears early in healing and is later replaced by Type I, and factors that impair collagen synthesis, such as vitamin C deficiency and medications, delay healing.

Biomaterials. Collagen-based scaffolds are used in cartilage repair and tissue engineering, and their design is informed by collagen structure, crosslinking and degradation.

Elastin

The third matrix macromolecule. Elastin completes the set. It is the structural protein responsible for elastic recoil in tissues that must stretch and rebound: the ligamentum flavum, aorta, skin and lung. The ligamentum flavum is the most elastin-rich ligament, roughly 80% elastin, which is why it stays taut and does not buckle into the spinal canal.

Assembly. Soluble tropoelastin is secreted and deposited onto a scaffold of fibrillin-1 microfibrils, then crosslinked into the insoluble polymer by lysyl oxidase, the same copper-dependent enzyme used for collagen, through the unique desmosine and isodesmosine crosslinks.

Disease. Fibrillin-1 (FBN1) mutations cause Marfan syndrome, the microfibril defect dysregulating TGF-beta signalling. Elastin (ELN) defects cause cutis laxa and supravalvular aortic stenosis (Williams syndrome), and failure of copper-dependent crosslinking (Menkes, lathyrism) weakens elastin as well as collagen.

Collagen is built as a hierarchy, from alpha chain to triple helix, fibril and fibre.

View larger

The triple helix

The Gly-X-Y repeat. Glycine sits at every third residue. It is the smallest amino acid and the only one small enough to fit in the centre of the helix, so any other amino acid in the glycine position disrupts it. The X position is often proline (28%) and the Y position often hydroxyproline (38%), and both stabilise the helix.

Left-handed chains, right-handed helix. Each alpha chain is a left-handed helix of the polyproline II type, with three residues per turn, an extended structure unlike the compact alpha-helix. Three chains wrap round one another into a right-handed triple helix, with the glycines along the central axis. There are no hydrogen bonds within a chain; the hydrogen bonds run between chains.

The tropocollagen molecule. The finished molecule is 300 nm long, 1.5 nm in diameter and about 300 kDa. Type I has two alpha-1(I) chains and one alpha-2(I), while Type II has three identical alpha-1(II) chains, a homotrimer.

Biosynthesis

Inside the cell, then outside. The first four steps take place within the cell, in the rough endoplasmic reticulum (RER) and Golgi, and the last three in the matrix. Two steps depend on a cofactor, vitamin C for hydroxylation and copper for crosslinking, and each deficiency has its disease.

Scurvy. Vitamin C deficiency impairs prolyl and lysyl hydroxylase activity, and scurvy affects all collagen types. Collagen is still synthesised but lacks adequate hydroxyproline, so the triple helix is unstable and denatures at body temperature. It presents with bleeding gums, poor wound healing and, in children, bone abnormalities, and is treated with vitamin C supplementation.

Fibrils and fibres

The quarter-stagger. Tropocollagen molecules align with a 67 nm stagger, the D-period. The offset leaves alternating gap zones (0.6D) and overlap zones (0.4D).

The D-band. On electron microscopy the stagger shows as the D-band, dark overlap zones alternating with light gap zones, and staining with phosphotungstic acid enhances it. The banding is the characteristic feature that identifies a collagen fibril.

Fibril diameter. Fibrils measure 20-500 nm across depending on the tissue. Type I fibrils are 50-200 nm and Type II fibrils smaller, at 20-40 nm. In cross-section the molecules are organised in quasi-hexagonal packing.

Fibrils into fibres. Fibrils bundle into collagen fibres micrometres in diameter, visible under light microscopy. The orientation of the fibres determines the anisotropy of the tissue.

Crosslinks

Immature crosslinks. Lysyl oxidase oxidises lysine to allysine, an aldehyde, which condenses to form dehydrolysinonorleucine (DHLNL) and lysinonorleucine (LNL). These are reducible Schiff bases, formed immediately.

Mature crosslinks. Pyridinoline (PYD) and deoxypyridinoline (DPD) develop over weeks to months. They are trifunctional, connecting three molecules, and are more stable and give greater tensile strength. They are found in bone, cartilage and dentin.

Crosslinks as markers. Urinary PYD and DPD are markers of bone resorption: released during bone turnover, they are not metabolised. They are elevated in osteoporosis, Paget disease and metastases.

Lathyrism. Lysyl oxidase requires copper. Copper deficiency, or inhibition by beta-aminopropionitrile (from the sweet pea, Lathyrus), prevents crosslinking: the fibrils form but are weak and soluble, and the result is lathyrism, with skeletal abnormalities, vascular rupture and poor wound healing. Penicillamine also interferes with crosslinking.

28 collagen types have been identified. Those that matter in orthopaedics are Types I, II, III, IV, V, IX, X and XI. Type I predominates in bone and tendon (90%), and Type II is the collagen of hyaline cartilage.

Families. Collagens are grouped by the structures they form:

• Fibril-forming: Types I, II, III, V, XI, which form D-banded fibrils
• FACIT (fibril-associated collagens with interrupted triple helices): Types IX, XII, XIV
• Network-forming: Types IV, VIII, X, in basement membranes and specialised networks
• Anchoring fibrils: Type VII, at the epidermis-dermis junction
• Transmembrane: Types XIII, XVII, XXIII

A proteoglycan is a core protein with covalently attached GAG side chains. Cartilage has the highest proteoglycan content, 4-7% of its wet weight.

Structure

Core protein and chains. The core protein is synthesised on ribosomes and varies in size, and the GAG chains are synthesised in the Golgi and attached to it. Proteoglycans vary in size and GAG composition with the function of the tissue, from small decorin through perlecan to aggrecan, the largest.

The attachment. GAGs attach to serine residues on the core protein through a tetrasaccharide linker, xylose-galactose-galactose-glucuronic acid. Keratan sulfate is the exception, attached to serine or threonine via N-acetylgalactosamine.

View larger

Glycosaminoglycans

The chains. GAGs are unbranched polysaccharides built from repeating disaccharide units.

Further points for each GAG:

• Chondroitin sulfate is the most abundant in cartilage, as the 4-sulfate (CS-A) or 6-sulfate (CS-C)
• Keratan sulfate has no uronic acid, carrying galactose instead
• Dermatan sulfate contains iduronic acid and binds decorin (regulating collagen fibrillogenesis)
• Heparan sulfate binds growth factors such as FGF and VEGF
• Hyaluronan is the only non-sulfated GAG, is not attached to a core protein, and is synthesised at the cell surface

Why the charge matters. Sulfate (SO₄⁻) and carboxyl (COO⁻) groups give GAG chains a high fixed negative charge density. That charge creates a Donnan osmotic pressure that draws water and cations (Na⁺, Ca²⁺) into the tissue, and in cartilage the resulting swelling pressure provides compressive stiffness.

The major proteoglycans

Aggrecan. The largest proteoglycan, 2-3 million Da, has a 220-250 kDa core protein carrying about 100 chondroitin sulfate and about 60 keratan sulfate chains. It provides the compressive stiffness of cartilage, and it turns over slowly, with a year-long half-life.

The aggregate. 50-100 aggrecan molecules bind a central hyaluronan backbone, up to 4000 nm long, through their G1 domains, and link protein (40-45 kDa), found only with aggrecan, stabilises the binding. The aggregate reaches 50-200 million Da, and its osmotic swelling pressure resists compression.

The aggrecan core protein is organised into domains:

• G1: binds hyaluronan
• Interglobular domain (IGD): the proteolysis site
• G2: function unclear
• Chondroitin sulfate-attachment regions and a keratan sulfate-attachment region
• G3: C-terminal, lectin-like

Decorin and biglycan. Both are small leucine-rich proteoglycans (SLRPs) with a 40 kDa core that regulate collagen fibrillogenesis. Decorin, in tendon, ligament, bone and cartilage, carries one dermatan sulfate or chondroitin sulfate chain, 90-140 kDa in total. It binds Type I and II collagen fibrils, regulates fibril diameter and spacing, and has anti-fibrotic properties. Biglycan, in bone and tendon, carries two such chains and binds growth factors (TGF-β, BMPs).

Perlecan. A large modular proteoglycan of basement membranes, with a 470 kDa core and multiple heparan sulfate chains. It serves filtration and acts as a growth factor reservoir, binding growth factors and regulating angiogenesis.

Versican. A large chondroitin sulfate proteoglycan, abundant in loose connective tissue, with a role in cell adhesion and migration.

Lubricin

Boundary lubrication. Lubricin (proteoglycan-4, PRG4, also called superficial zone protein, SZP) is a mucinous proteoglycan, distinct from the large aggregating aggrecan, secreted by superficial-zone chondrocytes and synovial lining cells. Its central mucin domain carries O-linked GAG-like sugars that make it amphiphilic, so it adsorbs to the cartilage surface and provides boundary lubrication. That is the dominant lubrication mode at low velocity and high load, protecting the surface where a fluid film cannot form, and it works alongside hyaluronan and interstitial fluid pressurisation.

When it fails. Loss-of-function PRG4 mutations cause camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome, with congenital joint contractures and non-inflammatory arthropathy. Lubricin depletion is implicated in post-traumatic and osteoarthritic surface wear.

View larger

Glycine substitutions, defective hydroxylation/crosslinking, and proteoglycan-processing defects all converge on connective-tissue fragility but differ in the molecule affected and the dominant phenotype. This table is high-yield for distinguishing the classic ECM diseases in a viva.

Global Relevance and Epidemiology

• Collagen and proteoglycan biochemistry is core basic-science content across all major fellowship examinations.
• Osteoarthritis, the dominant downstream disease of proteoglycan/collagen failure, affects an estimated 500+ million people worldwide and is a leading global cause of years lived with disability.
• Heritable disorders provide the natural "knockout" experiments: OI incidence is roughly 1 in 15,000-20,000 births; EDS collectively around 1 in 5,000.

Side-by-Side Guidance (ECM-Targeted OA Therapies)

Registry & Practice Variation

• Joint registries (NJR UK, AJRR US, AOANJRR Australia, Swedish/Norwegian registries) capture the end-stage arthroplasty outcomes of cartilage matrix failure and increasingly track cartilage-repair and biologic procedures.
• High-resource settings: access to cell-based cartilage repair (ACI/MACI), osteochondral grafting and quantitative MRI of cartilage matrix (T1rho, dGEMRIC) for early matrix assessment.
• Limited-resource settings: emphasis on conservative load management, weight optimisation and addressing nutritional collagen cofactors (vitamin C, copper) where deficiency is endemic; advanced biologics are often unavailable.